
    
      PROTOCOL OUTLINE: This is a dose escalation study. Patients receive an escalating dose of
      recombinant human insulin-like growth factor I (IGF-I). IGF-I is given subcutaneously twice a
      day. The dose of IGF-I is increased each day for 4 days. Glucose is administered
      intravenously, when necessary, to prevent hypoglycemia.

      Following the study treatment patients resume prior medication and may undergo surgery.

      Completion date provided represents the completion date of the grant per OOPD records
    
  